Advaxis, a biotech developing the next-generation of immunotherapies for cancer and infectious diseases, announced it will present at the 15th Annual BIO CEO & Investor Conference on February 11th at 9:30am EST in the Basildon room at the Waldorf-Astoria in New York City.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research - UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Thomas Moore, Chairman and CEO of Advaxis, will provide additional information on its Phase 2 study of ADXS-HPV in recurrent/refractory cervical cancer in 110 patients in India. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
In addition to providing ongoing social media coverage of the conference, MissionIR will issue a special broadcast to subscribers profiling companies scheduled to deliver a presentation. To sign up for The Mission Report, visit MissionIR.com.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net